Results 41 to 50 of about 3,958 (169)

Mitotane-Induced Endocrine Alterations in Children with Adrenocortical Carcinoma: Clinical Implications from a 20-Year Retrospective Study

Children
Background/Objectives: Mitotane is a key component in the treatment of adrenocortical carcinoma (ACC), but its endocrine side effects in children remain under-characterized. Methods: We conducted a retrospective analysis of 11 pediatric patients (6 males,
Gerdi Tuli, Jessica Munarin, Stefano Gabriele Vallero, Matilde Piglione, Eleonora Biasin, Luisa De Sanctis, Franca Fagioli   +6 more
doaj   +1 more source

Mitotane (op’DDD) restores growth and puberty in nine children with Cushing’s disease

Endocrine Connections, 2018
To investigate whether low-dose mitotane (up to 2 g/day) could be a temporary therapeutic alternative to transsphenoidal surgery (TSS) in pediatric Cushing’s disease (CD). Twenty-eight patients with CD aged 12.2 years (± 2.2) were referred to our center.
Emmanuelle Motte, Anya Rothenbuhler, Stephan Gaillard, Najiba Lahlou, Cécile Teinturier, Régis Coutant, Agnès Linglart   +6 more
doaj   +1 more source

Neurological adverse events of mitotane in adrenocortical carcinoma: results of a pilot study

Frontiers in Oncology, 2023
IntroductionMitotane, the only drug approved by the Food and Drug Administration (FDA) for the treatment of adrenocortical carcinoma, is associated with several side effects including neurotoxicity. The aim of our study is to investigate the relationship
Marilda Mormando, Edvina Galiè, Marta Bianchini, Rosa Lauretta, Giulia Puliani, Antonio Tanzilli, Umberto Anceschi, Giuseppe Simone, Gianluca Petreri, Giuliana Graziano, Andrea Pace, Marialuisa Appetecchia   +11 more
doaj   +1 more source

Mitotane in the treatment of childhood adrenocortical carcinoma: a potent endocrine disruptor

Endocrinology, Diabetes & Metabolism Case Reports, 2018
Adrenocortical carcinoma (ACC) during childhood is a rare malignant tumor that frequently results in glucocorticoid and/or androgen excess. When there are signs of microscopic or macroscopic residual disease, adjuvant therapy is recommended with mitotane,
Philip D Oddie, Benjamin B Albert, Paul L Hofman, Craig Jefferies, Stephen Laughton, Philippa J Carter   +5 more
doaj   +1 more source

Systemic anti‐cancer therapy associated with the occurrence of peripheral neurotoxicity and, specifically, peripheral neuropathy

International Journal of Cancer, Volume 159, Issue 2, Page 460-466, 15 July 2026.
What's new? While the effectiveness of systemic anticancer therapy is well documented, it commonly causes severe toxicity. This study of the 467 systemic anticancer therapy agents currently approved globally for clinical and/or research purposes found that peripheral neurotoxicity is associated with 45% of classical chemotherapies, 21% of targeted ...
Cassie Higgins, Lynn R. Gauthier, Blair H. Smith, Lesley Colvin   +3 more
wiley   +1 more source

Complete Remission of Advanced Adrenocortical Cancer Following Mitotane Monotherapy: A Case Report and Literature Review of Predictive Markers

Frontiers in Oncology, 2021
Mitotane has been used for the treatment of adrenocortical cancer (ACC) for over 50 years. Despite its widespread use both in monotherapy and in combination with chemotherapeutics, our knowledge of its mechanism of action and therapeutic efficacy is ...
Judit Tőke, Zsuzsanna Jakab, Júlia Stark, Gergely Huszty, Péter Reismann, Miklós Tóth   +5 more
doaj   +1 more source

Pseudo‐Progression Observed During Immune Checkpoint Inhibitor Therapy for Advanced Adrenocortical Carcinoma

IJU Case Reports, Volume 9, Issue 3, May 2026.
ABSTRACT Introduction Adrenocortical carcinoma (ACC) is a rare and aggressive malignancy. Recent studies suggest that immune checkpoint inhibitors exhibit antitumor activity in selected ACC patients. Case Presentation We report a case of a 49‐year‐old man with advanced ACC and pulmonary metastasis treated with EDP‐M chemotherapy, followed by ...
Moeto Shimoda, Shinji Ohtake, Tetsuya Aoki, Jurii Karibe, Yosuke Shibata, Masashi Imano, Masahiro Inoue, Kazuki Kobayashi   +7 more
wiley   +1 more source

Pharmacogenomic analysis in adrenocortical carcinoma reveals genetic features associated with mitotane sensitivity and potential therapeutics

Frontiers in Endocrinology
BackgroundAdrenocortical carcinoma (ACC) is an aggressive endocrine malignancy with limited therapeutic options. Treating advanced ACC with mitotane, the cornerstone therapy, remains challenging, thus underscoring the significance to predict mitotane ...
Jie Zhang, Luming Wu, Tingwei Su, Haoyu Liu, Lei Jiang, Yiran Jiang, Zhiyuan Wu, Lu Chen, Haorong Li, Jie Zheng, Yingkai Sun, Hangya Peng, Rulai Han, Guang Ning, Lei Ye, Weiqing Wang   +15 more
doaj   +1 more source

Successful treatment of occult hyperadrenocorticism with mitotane but not trilostane in a dog

Veterinary Medicine and Science, 2021
Background Occult (or atypical) hyperadrenocorticism (HAC) shows clinical signs and laboratory abnormalities similar to classic hyperadrenocorticism, but normal signs in routine screening tests such as the corticotropin (ACTH) stimulation test and low ...
Su‐Min Park, Kyeong‐Bo Kim, Woo‐Jin Song, Hwa‐Young Youn   +3 more
doaj   +1 more source

Multimodal Cross‐Attentive Graph‐Based Framework for Predicting In Vivo Endocrine Disruptors

Advanced Science, Volume 13, Issue 21, 13 April 2026.
A multimodal cross‐attentive graph neural network integrates molecular graphs with androgen and estrogen adverse outcome pathway (AOP)–anchored in vitro assay signals to predict in vivo endocrine disruption. By fusing information on Tier‐1 AOP logits with chemical structures, the framework achieves high accuracy and provides assay‐traceable ...
Eder Soares de Almeida Santos, Gustavo Felizardo Santos Sandes, Artur Christian Garcia da Silva, Holli‐Joi Martin, Eugene N. Muratov, Rodolpho de Campos Braga, Bruno Junior Neves   +6 more
wiley   +1 more source